| Autor: |
RuizIrastorza, Guillermo, Gordo, Susana, Olivares, Nerea, Egurbide, MariaVictoria, Aguirre, Ciriaco |
| Zdroj: |
Arthritis Care and Research; August 2010, Vol. 62 Issue: 8 p1160-1165, 6p |
| Abstrakt: |
ObjectiveTo analyze whether changes in serum 25hydroxyvitamin D 25OHD levels affect activity, irreversible organ damage, and fatigue in systemic lupus erythematosus SLE.MethodsWe performed an observational study of 80 patients with SLE included in a previous crosssectional study of 25OHD, reassessed 2 years later. Oral vitamin D3was recommended in those with low baseline 25OHD levels. The relationship between changes in 25OHD levels from baseline and changes in fatigue measured by a 0–10 visual analog scale VAS, SLE activity measured by the Systemic Lupus Erythematosus Disease Activity Index SLEDAI, and irreversible organ damage measured by the Systemic Lupus International Collaborating ClinicsAmerican College of Rheumatology Damage Index SDI were analyzed.ResultsSixty patients took vitamin D3. Mean 25OHD levels increased among all treated patients P 0.044, in those with baseline vitamin D levels <30 ngml P< 0.001, and in those with baseline vitamin D levels <10 ngml P 0.005. Fiftyseven patients 71 still had 25OHD levels <30 ngml and 5 6 had 25OHD levels <10 ngml. Inverse significant correlations between 25OHD levels and the VAS P 0.001 and between changes in 25OHD levels and changes in the VAS in patients with baseline 25OHD levels <30 ngml P 0.017 were found. No significant correlations were seen between the variation of the SLEDAI or SDI values and the variation in 25OHD levels P 0.87 and P 0.63, respectively.ConclusionIncreasing 25OHD levels may have a beneficial effect on fatigue. Our results do not support any effects of increasing 25OHD levels on SLE severity, although they are limited by the insufficient 25OHD response to the recommended regimen of oral vitamin D3replacement. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Plný text